Adapt Pharma
Adapt Pharma is a pharmaceutical company that developed NARCAN Nasal Spray, the first FDA-approved nasal naloxone spray for opioid overdose reversal, serving public health agencies, healthcare providers, and biodefense customers. Acquired by Emergent BioSolutions in 2018.
- Company typePrivate
- Founded2014
- HeadquartersRadnor, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Adapt Pharma does
Adapt Pharma was a specialty pharmaceutical company founded in 2014 and headquartered in Radnor, United States, focused on developing and commercializing treatments for endemic public health threats, with a primary emphasis on opioid overdose response. The company's core product was NARCAN Nasal Spray, the first FDA-approved nasal naloxone spray for opioid overdose reversal, which received FDA approval in 2013 and became available over-the-counter in 2023. The company developed novel nasal spray drug delivery technology and biological countermeasures, ultimately distributing over 85 million doses of NARCAN across North America. Its customer base spanned public health agencies, healthcare providers, and communities addressing the opioid crisis, alongside national security and biodefense customers. Distribution occurred through B2B healthcare wholesale channels for commercial products and direct government contracts for biodefense products, with marketing conducted through organic social media (LinkedIn, Instagram, X), podcast content (Countermeasures on Spotify and Apple Podcasts), press releases, and investor relations communications.
Adapt Pharma firmographics
Firmographics- Name
- Adapt Pharma
- Website
- https://adaptpharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Adapt Pharma is a pharmaceutical company that developed NARCAN Nasal Spray, the first FDA-approved nasal naloxone spray for opioid overdose reversal, serving public health agencies, healthcare providers, and biodefense customers. Acquired by Emergent BioSolutions in 2018.
- Ownership category
- akta.pro rank
Adapt Pharma industry classification
Industry- Product category
- Pharmaceuticals - Opioid Overdose Treatment
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
- akta.pro secondary industries
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where Adapt Pharma is headquartered
LocationHeadquarters
- HQ city
- Radnor
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Adapt Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
Distribution channels2 records
Marketing channels10 records
Adapt Pharma product offering
Product offeringCore offering
Adapt Pharma developed and commercialized NARCAN Nasal Spray, the first FDA-approved nasal naloxone spray for the emergency treatment of opioid overdose. The company specialized in pharmaceutical development and manufacturing of medical countermeasures addressing public health threats, distributing over 85 million doses of NARCAN across North America. Following its acquisition by Emergent BioSolutions, the NARCAN business transitioned to over-the-counter availability in 2023.
Product overview
Adapt Pharma developed NARCAN Nasal Spray as its primary commercial product — the first nasal naloxone spray to receive FDA approval for opioid overdose reversal. The product portfolio consists of NARCAN Nasal Spray, which was the company's core over-the-counter offering for the opioid epidemic response.
Differentiator
Problem solved
Functional benefit
Products and services
- NARCAN Nasal Spray The first FDA-approved nasal naloxone spray for the emergency treatment of opioid overdose. It became available over-the-counter in 2023, and Emergent BioSolutions (formerly Adapt Pharma's NARCAN business) has distributed over 85 million doses across North America.
Companies that use Adapt Pharma
Customer profileSegments2 records
Ideal customer profiles2 records
Adapt Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Adapt Pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Administration for Strategic Preparedness and Response (ASPR)coreGovernment partner providing approximately $64.5 million contract modification for BAT (Botulism Antitoxin Heptavalent) to support U.S. Biodefense Strategy. ASPR is a division of the U.S. Department of Health and Human Services.
- Strategic Manufacturing PartnerscoreLeverages specialized in-house capabilities to support biopharma innovators, governments, and non-government organizations with their development and manufacturing needs.
- Saudi Food and Drug Authority (SFDA)minorRegulatory approval obtained for ACAM2000 (Smallpox and Mpox Vaccine) for the prevention of smallpox and mpox disease in high-risk individuals in Saudi Arabia.
Scale indicators2 records
Recent moves4 records
Expansion highlights3 records
Adapt Pharma competitors and assessment
Company assessmentBroad incumbents
- Emergent BioSolutions: Parent company of Adapt Pharma since 2018. Operates the NARCAN franchise as part of its broader biodefense and public health countermeasures portfolio, including BAT and ACAM2000. The closest comparable for capital structure, regulatory posture, and biodefense contract exposure.
- Indivior: Specialty pharmaceutical company focused on opioid use disorder treatments (e.g., Suboxone). Comparable in its focus on the opioid public health crisis and adjacent therapeutic categories.
- Teva Pharmaceutical Industries: Generic pharmaceutical manufacturer with naloxone products and broad OTC/generic infrastructure. Comparable as a potential generic competitor leveraging large-scale manufacturing and distribution for nasal naloxone.
- Sandoz (Novartis): Major generic pharmaceutical manufacturer offering naloxone products and broad OTC/generic capabilities. Comparable as a potential low-cost nasal naloxone entrant in retail channels.
Direct peers
- Amphastar Pharmaceuticals: Markets naloxone injectable products and has been a long-standing competitor in the opioid overdose reversal category. Comparable as a directly competing naloxone supplier to first responders and health systems.
- kaléo (Auvi-Q / Evzio): Developed Evzio, an auto-injector formulation of naloxone for opioid overdose reversal. Comparable as a direct competitor offering an alternative delivery device (auto-injector vs. nasal spray) for the same clinical indication.
- Hikma Pharmaceuticals: Manufactures and markets generic naloxone nasal spray products in the U.S. Comparable as a direct generic competitor to NARCAN in the post-OTC nasal naloxone category.
Emerging players
- Opiant Pharmaceuticals: Developed intranasal nalmefene (OPNT003) for opioid overdose. Comparable as a developer of nasal delivery opioid antagonists, with a next-generation alternative to NARCAN's naloxone.
Others
- Aptar Pharma: Leading supplier of nasal spray drug delivery devices and components to pharmaceutical companies. Comparable as the underlying device technology provider for nasal spray pharmaceutical products in the same category.
- West Pharmaceutical Services: Supplier of drug delivery components and containment systems used in nasal and injectable pharmaceutical products. Comparable as an enabling technology provider in the drug delivery ecosystem that underpins nasal spray products.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Adapt Pharma social profiles
Digital presenceAdapt Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adapt Pharma leadership team
Management profileNumber of profiles
Profiles4 records
Adapt Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adapt Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adapt Pharma
What does Adapt Pharma do?
Adapt Pharma developed and commercialized NARCAN Nasal Spray, the first FDA-approved nasal naloxone spray for the emergency treatment of opioid overdose. The company specialized in pharmaceutical development and manufacturing of medical countermeasures addressing public health threats, distributing over 85 million doses of NARCAN across North America. Following its acquisition by Emergent BioSolutions, the NARCAN business transitioned to over-the-counter availability in 2023.
Is Adapt Pharma a public or private company?
Adapt Pharma is a private company. It is classified as corporate owned and is currently acquired.
When was Adapt Pharma founded?
Adapt Pharma was founded in 2014. It employs 11 to 50 people.
Where is Adapt Pharma based?
Adapt Pharma is headquartered in Radnor, United States, in the North America region.
Who are Adapt Pharma's main competitors?
Broad incumbents on record are Emergent BioSolutions, Indivior, Teva Pharmaceutical Industries and Sandoz (Novartis). Direct peers are Amphastar Pharmaceuticals, kaléo (Auvi-Q / Evzio) and Hikma Pharmaceuticals. Opiant Pharmaceuticals is listed as an emerging player. Others are Aptar Pharma and West Pharmaceutical Services.
Does Adapt Pharma have an API?
No public API is recorded for Adapt Pharma.
What industry is Adapt Pharma in?
Adapt Pharma's product category is Pharmaceuticals - Opioid Overdose Treatment. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.